TheraRadar
← Back
Data updated: May 24, 2026

HORIZON

Specialty
Pharmaceuticals

HORIZON is a specialty pharmaceutical company with 5 FDA-approved products.

2010
Since
5
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

Key Drugs

Top revenue-generating and strategically important drugs approved in the last 15 years. These represent the company's core commercial portfolio.

PROCYSBI
Rare Disease

Nephropathic Cystinosis

Approved 2013

Recent FDA Approvals

New drug approvals (NDA/BLA) in the last 2 years. Shows novel drugs only, excluding generics and label supplements.

No recent approvals

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

No indication data

Pipeline Snapshot

Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • PROCYSBI leads revenue
  • • Drug-level revenue analysis
View revenue breakdown →

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking
View full pipeline →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis
View patent timeline →

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Compare with competitor →
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling